This article is more than 5 years old. Information may no longer be current.

Sanofi-Aventis, Bristol-Myers Squibb Collect Damages in Clopidogrel Litigation

Issue: March/April 2012

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Apotex has paid Sanofi-Aventis and Bristol-Myers Squibb $442,209,362 to satisfy the ruling of the patent infringement case brought by the two manufacturers in March 2002.

The payment follows the decision of the US Court of Appeals for the Federal Circuit in October 2011, and represents the final phase of the clopidogrel (Plavix) patent litigation between the companies. Sanofi-Aventis and Bristol-Myers Squibb were also awarded $1,258,682 in post-judgment interest and $900,000 in costs in addition to the damages.